Navigation Links
Can cancer drugs combine forces?
Date:8/16/2007

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL). If their disease returns, because BCR-ABL mutants emerge that are resistant to the effects of imatinib, individuals are treated with a drug known as dasatinib (SPRYCEL), which targets BCR-ABL in a different way. However, patients that relapse after treatment with dasatinib, because BCR-ABL mutants emerge that are resistant to the effects of this drug, are now beginning to be seen in the clinic. Researchers from Memorial Sloan-Kettering Cancer Center, New York, now suggest that treating patients with a combination of the drugs might decrease the chance of the cancer returning, or at the very least increase the time before a relapse occurs

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, Charles Sawyers and colleagues show that 2 of 12 patients whose cancer had returned after treatment with dasatinib responded to retreatment with imatinib. Analysis of the BCR-ABL proteins from these patients revealed that their BCR-ABL had only the dasatinib-resistance mutation. By contrast, the BCR-ABL proteins of the other patients had either a single mutation that rendered the protein resistant to both dasatinib and imatinib or had two mutations, one rendering the protein resistant to imatinib and one rendering the protein resistant to dasatinib. A third drug that can target dasatinib- and imatinib-resitant BCR-ABL is currently in clinical trials. The authors therefore suggest that rather than treating CML patients with the drugs that target BCR-ABL sequentially, they should receive all the drugs when they are first diagnosed with the disease so that the emergence of the drug-resistant forms of BCR-ABL might be prevented, or at least delayed.


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Brenntag Specialties, Inc.(BSI) , is pleased ... Beverage and Dietary Supplement market segments across the western United ... east of the Rocky Mountains since 2012. Consistent performance in business development ...
(Date:2/8/2016)... ... February 08, 2016 , ... A man who has struggled to quit smoking, a man ... , was determined to find solutions to his problems – and he did. Now Nabat, ... is ready to introduce his breakthrough inventions to the world and better people's lives. His ...
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
(Date:2/8/2016)... ... ... the Rocky Mountain region’s longest running and impressive garden and home show where you ... the most incredible gardens and home improvement experts that attend this amazing show. ... 700 14th St. Denver CO, is an exciting event that Performance Mobility has enjoyed ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today ... U.S. Food and Drug Administration (FDA) on February 4, ... hold on the clinical studies being conducted under the ... clinical hold impacts part of the clinical work currently ... planned clinical trials. --> ...
(Date:2/5/2016)... IRVINE, Calif. , Feb. 5, 2016 /PRNewswire/ ... leading global aesthetic device company, announced today that ... Syneron Candela North America, is scheduled to participate ... Global Healthcare Conference on February 11, 2016 in ... conference will allow institutional investors to meet with ...
(Date:2/5/2016)... http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> Research and ...
Breaking Medicine Technology: